Onconova Therapeutics Inc.
375 Pheasant Run
Newtown
New Jersey
18940
United States
Tel: 609-844-7735
Website: http://www.onconova.com/
Email: info@onconova.com
241 articles about Onconova Therapeutics Inc.
-
Onconova Therapeutics, Inc. Announces Closing of $21 Million Public Offering of Common Stock
9/28/2021
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced the closing of its previously announced underwritten public offering.
-
Onconova Therapeutics, Inc. Announces Pricing of $21 Million Public Offering of Common Stock
9/24/2021
Onconova Therapeutics, Inc. today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $4.20 per share.
-
Onconova Therapeutics, Inc. Announces Proposed Public Offering of Common Stock - Sep 23, 2021
9/23/2021
Onconova Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing novel products to treat cancer, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
-
Onconova Therapeutics Announces Encouraging Clinical Data Supporting the Anti-Cancer Activity of Rigosertib-Nivolumab Combination in Advanced KRAS+ Non-Small Cell Lung Cancer
9/22/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced preliminary safety and efficacy data from an investigator-initiated Phase 1/2a trial of oral rigosertib plus the immune checkpoint inhibitor nivolumab in advanced KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC).
-
Onconova Therapeutics Announces Upcoming Presentation at the 3rd Annual RAS Targeted Drug Development Summit
9/20/2021
Onconova Therapeutics, Inc. today announced an upcoming presentation at the 3rd Annual RAS Targeted Drug Development Summit
-
Onconova Therapeutics Announces Participation at the Upcoming H.C. Wainwright 23rd Annual Global Investment Conference
9/9/2021
Onconova Therapeutics, Inc. today announced that the Company will be participating in the H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021.
-
Onconova Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateConference call and live webcast at 4:30 p.m. ET today
8/12/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the three months ended June 30, 2021 and provided a business update.
-
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2021 Financial Results on August 12, 2021
8/5/2021
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its second quarter 2021 financial results on Thursday, August 12, 2021.
-
Onconova Therapeutics Provides an Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer
6/28/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced metastatic KRAS mutated (KRAS+) non-small cell lung cancer (NSCLC).
-
Onconova Therapeutics Regains Compliance with Nasdaq Continued Listing Requirement - June 22, 2021
6/22/2021
Onconova Therapeutics, Inc. announced that on June 17, 2021 it received a letter from The Nasdaq Stock Market LLC stating that the Company has regained compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550, as the Company’s common stock had a closing bid price of at least $1.00 per share for 18 consecutive business days, from May 21, 2021 to June 16, 2021.
-
Onconova Therapeutics Announces the Peer-Reviewed Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined with Immune Checkpoint Blockade
6/17/2021
Onconova Therapeutics, Inc. today announced the publication of a preclinical study in the journal Molecular Cancer.
-
Onconova Therapeutics Announces Participation in A.G.P.’s Upcoming Virtual Summer Healthcare Symposium
6/10/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that members of the Company’s management team will participate in A.G.P.’s Virtual Summer Healthcare Symposium on Thursday, June 17, 2021.
-
Onconova Therapeutics Announces Upcoming Presentation at 2021 BIO Digital
6/3/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova has been selected to present at 2021 BIO Digital, being held virtually June 10-11 and 14-18, 2021.
-
Onconova Therapeutics Announces the Appointment of Mark Gelder, M.D., as Chief Medical Officer
6/1/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Mark Gelder, M.D. will be joining Onconova as Chief Medical Officer
-
Onconova Therapeutics Announces the Initial Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of ON 123300
5/21/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the first patient has been dosed in the U.S. Phase 1 clinical trial of ON 123300, the Company’s proprietary, novel multi-kinase inhibitor.
-
Onconova Therapeutics Announces Reverse Stock Split and Decrease in Authorized Shares
5/20/2021
Onconova Therapeutics, Inc. (Nasdaq: ONTX) (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced a one-for-fifteen reverse stock split of its common stock, effective May 20, 2021.
-
Onconova Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
5/17/2021
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced financial results for the three months ended March 31, 2021 and provided a business update.
-
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2021 Financial Results on May 17, 2021Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, May 17.
5/10/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company intends to release its first quarter 2021 financial results on Monday, May 17, 2021.
-
Onconova Announces First Patient Dosed in Investigator-Initiated Phase 2 Study of Rigosertib in Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma
4/22/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX) , a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced today that the first patient has been dosed in an investigator-initiated Phase 2 study to assess the efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa (RDEB)-associated locally advanced/metastatic squamous cell carcinoma (SCC).
-
Onconova Therapeutics Announces Enrollment in Second Cohort of Phase 1 Study with ON 123300 in ChinaCorporate Partner HanX Biopharmaceuticals enrolled third patient in 80 mg group
4/1/2021
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announces that its corporate partner HanX Biopharmaceuticals has enrolled three patients in the second dosing cohort of its Phase 1 study with ON 123300 in HR+ HER2- metastatic breast cancer and other advanced relapsed/refractory cancers in China.